What is the rationale for novel combination therapies?
Niels van de Donk
How can we overcome ibrutinib resistance?
Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure
Anas Younes et al.
Determining the best course of treatment for younger patients with relapsed/refractory CLL
The use of trastuzumab and biosimilars in the treatment of breast cancer